Topical Solution 0.5%
Podofilox Topical Solution is an antimitotic drug which can be chemically synthesized or purified from the plant families Coniferae and Berberidaceae (e. g. species of Juniperus and Podophyllum). Podofilox Topical Solution 0.5% is formulated for topical administration. Each milliliter of solution contains 5 mg of podofilox, in a vehicle containing lactic acid and sodium lactate in alcohol 95%, USP.
Podofilox Topical Solution 0.5% is indicated for the topical treatment of external genital warts (Condyloma acuminatum). This product is not indicated in the treatment of perianal or mucous membrane warts (see PRECAUTIONS).
Although genital warts have a characteristic appearance, histopathologic confirmation should be obtained if there is any doubt of the diagnosis. Differentiating warts from squamous cell carcinoma (so-called "Bowenoid papulosis") is of particular concern. Squamous cell carcinoma may also be associated with human papillomavirus but should not be treated with Podofilox Topical Solution 0.5%.
Clinical Trials Related to Podofilox (Podofilox Topical)
Bortezomib, Mitoxantrone, Etoposide, and Cytarabine in Relapsed or Refractory Acute Myeloid Leukemia [Recruiting]
RATIONALE: Bortezomib may stop the growth of cancer cells by blocking some of the enzymes
needed for cell growth. Drugs used in chemotherapy, such as mitoxantrone, etoposide, and
cytarabine, work in different ways to stop the growth of cancer cells, either by killing the
cells or by stopping them from dividing. Giving bortezomib together with combination
chemotherapy may kill more cancer cells.
PURPOSE: This phase I trial is studying the side effects and best dose of bortezomib when
given together with mitoxantrone, etoposide, and cytarabine in treating patients with
relapsed or refractory acute myeloid leukemia.
Bortezomib and Vorinostat as Maintenance Therapy After Autologous Stem Cell Transplant for Non-Hodgkin Lymphoma [Recruiting]
This phase II trial is studying the side effects and how well bortezomib and vorinostat work
in treating patients with non-Hodgkin lymphoma (NHL) after an autologous stem cell
transplant (ASCT). Bortezomib and vorinostat in the laboratory may stop the growth of
lymphoma cells and make them more likely to die. Giving bortezomib together with vorinostat
after an ASCT may thus kill any lymphoma cells that remain after transplant.
Rituximab, Combination Chemotherapy, Filgrastim (G-CSF), and Plerixafor in Treating Patients With Non-Hodgkin Lymphoma Undergoing Mobilization of Autologous Peripheral Blood Stem Cells [Recruiting]
This phase II trial is studying how well giving rituximab, ICE combination chemotherapy, and
G-CSF together with plerixafor works in treating patients with non-Hodgkin lymphoma
undergoing mobilization of autologous peripheral blood stem cells. Giving chemotherapy (ICE)
with monoclonal antibodies, such as rituximab, stops the growth of cancer cells by stopping
them from dividing or by killing them and helps get better autologous stem cell product.
Giving colony-stimulating factors, such as filgrastim (G-CSF), and plerixafor helps stem
cells move from the patient's bone marrow to the blood so they can be collected and stored
for future autologous transplant
Autologous Stem Cell Transplant Followed by Donor Stem Cell Transplant In Treating Patients With Relapsed or Refractory Lymphoma [Recruiting]
This phase I/II trial is studying how well autologous stem cell transplant followed by donor
stem cell transplant works in treating patients with lymphoma that has returned or does not
respond to treatment. Peripheral blood stem cell transplant using stem cells from the
patient or a donor may be able to replace immune cells that were destroyed by chemotherapy
used to kill tumor cells. The donated stem cells may also help destroy any remaining cancer
cells (graft-versus-tumor effect).
Bendamustine Hydrochloride, Rituximab, Etoposide, and Carboplatin in Treating Patients With Relapsed or Refractory Diffuse Large B Cell Lymphoma or Hodgkin Lymphoma [Recruiting]
This phase I/II trial is studying the side effects and best dose of bendamustine
hydrochloride when given together with carboplatin, etoposide, and rituximab in treating
patients with relapsed or refractory diffuse large B cell lymphoma or Hodgkin lymphoma.
Drugs used in chemotherapy, such as bendamustine hydrochloride, etoposide, and carboplatin,
work in different ways to stop the growth of cancer cells, either by killing the cells or by
stopping them from dividing. Monoclonal antibodies, such as rituximab, can block cancer
growth in different ways. Some block the ability of cancer cells to grow and spread. Others
find cancer cells and help kill them or carry cancer-killing substances to them. Giving
bendamustine hydrochloride together with carboplatin, etoposide, and rituximab may kill more
Page last updated: 2008-03-12